INSR and Alzheimer disease: Importantly, the combined treatments reduced AβPP-Aβ levels, the severity of AD pathology, including AβPP-Aβ neuritic plaques, and oligomeric AβPP-Aβ-mediated down-regulation of the insulin receptor.